Mesenbio is a preclinical stage biopharmaceutical company from the University of York. Our Cell Line Extracellular Vesicle Release (CLEVR) platform enables us to pursue a varied therapeutic pipeline by addressing the most prevalent bottleneck in extracellular vesicle therapeutics: consistency. We leverage our platform to produce a consistent, endless supply of therapeutically exciting extracellular vesicles. Our aim is to transform medicine by unlocking extracellular vesicles as a novel treatment modality. We have shown that our cells produce naturally bioactive extracellular vesicles with combined anti-inflammatory and pro-regenerative potential, and are pursuing an internal pipeline to address musculoskeletal disease that takes advantage of this unique capability. CLEVR can also enable discovery and development of interventions for other indications, and we are happy to discuss potential synergies with new partners.